Abstract:Standard therapy for patients with hypothyroidism is replacement with synthetic thyroxine (T4). However, thyroxine plus triiodothyronine (T3) replacement therapy resulted in marked improvements in several items of the Profile of Mood States and in a few indices of psychometric function and quality of life. The adequacy of thyroxine alone versus thyroxine plus triiodothyronine to treat hypothyroidism has yielded conflicting results. Therefore, we conducted a systematic review of all included published, randomized controlled trials to evaluate the effects of thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. We electronically searched Medline, Embase, the Cochrane Library, and China National Infrastructure. We also manually searched the Chinese Journal of Isotopes, Radiologia pratica, and the Chinese Journal of Endocrinology and Metabolism. A total of 10 randomized, double-blind trials (six crossovers, four parallel trials) were identified. Pooled analyses were suggestive of a statistically significant increase of free and total triiodothyronine, significant decrease of serum-free and total thyroxine in patients treated with thyroxine plus triiodothyronine, weighted mean difference (WMD) 0.03, −31.25, 2.19, 3.00; 95% confidence interval (CI) −0.14 to 0.20, −47.04 to −15.47, 0.46–3.92, 1.64–4.36, respectively. Thyroxin alone indicated significant benefits for psychological or physical well-being in terms of the General Health Questionnaire-28 (WMD: −2.90; 95% CI: −3.18 to −2.63), general health (WMD: −0.38; 95% CI: −0.71 to −0.05), physical component summary (WMD: 0.7; 95% CI: 0.53–0.87), and mental component summary (WMD: 0.58; 95% CI: 0.25–0.75); physical functioning (WMD: 1.60; 95% CI: 1.29–1.90), role–physical test (WMD: 3.60; 95% CI: 2.66–4.54), bodily pain (WMD: 2.50; 95% CI: 2.11–2.88), role–emotional (WMD: 2.08; 95% CI: 1.17–2.99), mental health (WMD: 1.30; 95% CI: 0.97–1.64) in items of the Short Form-36 Health Survey; general well-being in items of the Thyroid Symptom Questionnaire (WMD: −1.90; 95% CI: −2.48 to −1.32); better performance in the Letter Number Sequencing-working memory test in items of cognitive performance scores (WMD: 1.10; 95% CI: 0.08–2.13), significant treatment effect for blurred vision, aches, and pain (WMD: −4.66, −0.80; 95% CI: −5.339 to −4.00, −1.34 to −0.26, respectively). However, T4 plus T3 replacement improved cognitive performance (WMD: −0.49; 95% CI: −0.90 to −0.08). No significant statistical differences were found in biochemical variables, mood states clinical variables, adverse effects, and drop-out. In subgroup analysis, two included studies examined the relationship between mental improvement and causes of hypothyroidism, autoimmune, and nonautoimmune hypothyroidism, respectively. T4 alone suggested significantly higher total T4 (autoimmune and nonautoimmune thyroid, WMD: 4.5, 3.7; 95% CI: 2.24–6.76, 1.66–5.74, respectively), and significantly decreased thyroid-stimulating hormone (WMD: −0.05; 95% CI: −0.09 to −0.01). Statistically significant improvement occurred in pairs correctly recalled in the Digit Symbol Test for T4 plus T3 replacement (WMD: −1.60; 95% CI: −2.97 to −0.23) for nonautoimmune thyroid. In conclusion, on the basis of data from recent studies, we conclude that combined T4 and T3 treatment does not improve well-being, cognitive function, or quality of life compared with T4 alone. T4 alone may be beneficial in improving psychological or physical well-being. According to the current evidence, T4 alone replacement may remain the drug of choice for hypothyroid patients.

A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism

Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients

Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism

Thyroxine Alone or Thyroxine Plus Triiodothyronine Replacement Therapy for Hypothyroidism

Triiodothyronine levels in athyreotic pediatric patients during levothyroxine therapy

Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia

Clinical comparative efficacy and therapeutic strategies for the Hashimoto's thyroiditis: A systematic review and network meta-analysis

Triiodothyronine/Thyroxine Ratio as a Marker of Clinical Response to Levothyroxine Replacement in Patients With Hypothyroidism

Treatment Preferences in Patients with Hypothyroidism: an Analysis of Eleven Randomized Controlled Trials

Levothyroxine Therapy in Thyrodectomized Patients

Optimizing the treatment of hypothyroidism

Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary artery disease

Combined T4 + T3 Therapy Versus T4 Monotherapy Effect on Psychological Health in Hypothyroidism: A Systematic Review and Meta‐analysis

Levothyroxine Interactions with Food and Dietary Supplements–A Systematic Review

Effect of Addition of Thyroxine in the Treatment of Graves’ Disease: A Systematic Review

The Impact of Levothyroxine Therapy on Pregnancy and Neonatal Outcomes in Euthyroid Pregnant Women with Thyroid Autoimmunity: A Systematic Review, Meta-Analysis and Trial Sequential Analysis

Alternative routes of levothyroxine administration for hypothyroidism

The Impact of Levothyroxine Therapy on the Pregnancy, Neonatal and Childhood Outcomes of Subclinical Hypothyroidism During Pregnancy: an Updated Systematic Review, Meta-Analysis and Trial Sequential Analysis.

Pregnancy and Neonatal Outcomes With Levothyroxine Treatment in Women With Subclinical Hypothyroidism Based on New Diagnostic Criteria: A Systematic Review and Meta-Analysis